India-based Sun Pharmaceutical Industries (Sun Pharma) will acquire US-based Concert Pharmaceuticals for equity consideration of $576 million to strengthen its global dermatology franchise. Concert Pharmaceuticals is developing deuruxolitinib, a novel, deuterated, oral Janus kinases JAK1/2 inhibitor for the treatment of Alopecia Areata, an autoimmune dermatological disease resulting in partial or complete loss of hair on […]
Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with advanced breast cancer. The Indian pharma company will make the anti-cancer drug available under the brand name PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg. Palbociclib has approval in […]
Sun Pharmaceutical Industries has secured approval for SEZABY (phenobarbital sodium powder for injection) from the US Food and Drug Administration (FDA) for the treatment of neonatal seizures. According to Sun Pharmaceutical, the approval makes SEZABY the first and only product to be indicated specifically in the US for treating neonatal seizures in term and preterm […]
Sun Pharmaceutical Industries said that its subsidiary Taro Pharmaceutical Industries’ fully-owned subsidiary Taro Pharmaceuticals U.S.A., has acquired Delaware-based Galderma Holdings, Japan-based Proactiv YK, Canada-based The Proactiv Company, and other assets of The Proactiv Company Sari. The consideration for the deal is $99.28 million. Galderma Holdings, which is incorporated in Delaware, Proactiv YK, The Proactiv Company, […]
Sun Pharmaceutical Industries said that one of its fully-owned subsidiaries has secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. According to the Indian pharma company, the generic product approval is based on AmBisome Liposome […]
Sun Pharma Consumer Healthcare, a unit of Sun Pharmaceutical Industries (Sun Pharma), has made its entry into the nutrition bar segment in India through the launch of Revital NXT. According to Sun Pharma, Revital NXT is a brand extension of the health supplement Revital H. The nutrition bar is packed with natural ginseng, 16 vitamins […]
Five Indian pharma companies – Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals will join forces to undertake a clinical trial of Molnupiravir, an investigational oral anti-viral drug for the treatment of mild Covid-19 in India. The clinical trial of Molnupiravir will be in an outpatient setting. Molnupiravir is being developed […]
Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene, a fully-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation pertaining to generic Revlimid (lenalidomide). The patent litigation is about the submission of an abbreviated new drug application (ANDA) for a generic version of lenalidomide […]
Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to the latter’s baricitinib in India. The Indian pharma company Sun Pharma will manufacture and distribute baricitinib in India. Baricitinib has been granted restricted emergency use by India’s Central Drugs Standard […]
Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for CEQUA (cyclosporine ophthalmic solution) 0.09%, a significant advancement in the treatment of keratoconjunctivitis sicca, commonly known as dry eye disease. This approval introduces a new therapeutic option for a condition that affects millions worldwide, addressing a substantial unmet medical […]
